Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase Ib, randomized, placebo controlled, double blind study to determine the safety, viral suppression, pharmacokinetics and immune modulatory effects of treatment with aprepitant (Emend) in HIV infected individuals

Trial Profile

A phase Ib, randomized, placebo controlled, double blind study to determine the safety, viral suppression, pharmacokinetics and immune modulatory effects of treatment with aprepitant (Emend) in HIV infected individuals

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Aprepitant (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 18 Jul 2010 Results have been presented at the 18th International AIDS Conference.
    • 27 Apr 2010 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top